Kineta sells Genentech and Merck deals to investor ahead of TuHURA merger

Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA Biosciences, the biotech has agreed to sell the deals to an investment firm, offload a pain prospect to Pacira Pharmaceuticals and scrap its pact with GigaGen.